Validcare announced an integration partnership with Galen F P Solutions to enhance their Study platform, designed to help pharmaceutical sponsors complete clinical trials predictably and within budget constraints.
The Challenge
Delays in drug approvals cost their creators an average of $1MM USD per day, according to University of Texas research. The partnership combines Validcare’s patient-centric automation capabilities with Galen’s clinical operations expertise to address this challenge.
Executive Perspectives
Patrick McCarthy, Validcare’s CEO, emphasized that the combined solution addresses longstanding industry challenges: “For too long, the pharmaceutical industry has tolerated cost overruns, trial cancellations, delayed product approvals” and related financial impacts. He highlighted that the platform now gives sponsors “visibility, tools, metrics and control.”
Steve Galen, founder of Galen F P Solutions, noted their approach incorporates “over twenty years of experience designing and executing clinical trials” combined with data-driven optimization strategies.
Solution Benefits
The integrated platform targets small-to-mid-size (SMID) biotech and pharma companies, consolidating capabilities previously available only to larger organizations. Features include:
- Automated participant and clinical operations management
- Trial performance metrics
- ROI visibility throughout the clinical lifecycle